Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 11/20 | 0.44 |
| ▸ | MME | P08473 | 10/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | KYNU | Q16719 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607515 | 0.89 | ACE2 (0.45) | ACE2ECE1MMEKYNU | |
| SCHEMBL28607514 | 0.87 | ACE2 (0.46) | ACE2ECE1MMEKYNUELANE | |
| SCHEMBL23881871 | 0.87 | ACE2 (0.48) | ACE2NPC1RAB9AECE1MME | |
| SCHEMBL28603333 | 0.86 | CASP1 (0.48) | ACE2ECE1MMECASP1 | |
| SCHEMBL28606134 | 0.85 | F2 (0.43) | ACE2ECE1MMEELANEPRTN3 | |
| SCHEMBL28598306 | 0.85 | MEN1 (0.45) | ACE2ECE1MME | |
| SCHEMBL28597382 | 0.83 | ATM (0.51) | ACE2ECE1MMEKYNUELANE | |
| SCHEMBL28610449 | 0.82 | F2 (0.47) | ACE2ECE1MMEELANEPRTN3 | |
| SCHEMBL28607517 | 0.82 | ACE2 (0.43) | ACE2ECE1MME | |
| SCHEMBL28607881 | 0.82 | NPC1 (0.45) | ACE2NPC1RAB9AECE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166182-A | Aminopeptidase A inhibitor and pharmaceutical composition comprising the same | 量子基因公司 | 2021-07-23 | — | — | CN | disclosed |